# Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD

> **NCT02633527** · PHASE2 · COMPLETED · sponsor: **Supernus Pharmaceuticals, Inc.** · enrollment: 222 (actual)

## Conditions studied

- Attention-Deficit/Hyperactivity Disorder (ADHD)

## Interventions

- **DRUG:** Placebo
- **DRUG:** 100mg SPN-812
- **DRUG:** 200mg SPN-812
- **DRUG:** 300mg SPN-812
- **DRUG:** 400mg SPN-812

## Key facts

- **NCT ID:** NCT02633527
- **Lead sponsor:** Supernus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-01
- **Primary completion:** 2016-07-25
- **Final completion:** 2016-07-25
- **Target enrollment:** 222 (ACTUAL)
- **Last updated:** 2021-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02633527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02633527, "Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02633527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*